Focused On-demand Library for Nucleolar transcription factor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P17480

UPID:

UBF1_HUMAN

Alternative names:

Autoantigen NOR-90; Upstream-binding factor 1

Alternative UPACC:

P17480; A8K6R8

Background:

Nucleolar transcription factor 1, also known as Upstream-binding factor 1 and Autoantigen NOR-90, plays a pivotal role in ribosomal RNA gene transcription. It activates transcription mediated by RNA polymerase I by interacting with the SL1/TIF-IB complex and binds specifically to the upstream control element. This protein's function is crucial for the proper synthesis of ribosomal RNA, a fundamental process for cellular growth and proliferation.

Therapeutic significance:

Nucleolar transcription factor 1 is linked to Neurodegeneration, childhood-onset, with brain atrophy, a devastating condition characterized by progressive cortical atrophy, developmental delay, and loss of motor skills. Understanding the role of Nucleolar transcription factor 1 could open doors to potential therapeutic strategies for this neurodegenerative disease, offering hope for targeted interventions.